Sequencing Complex Diseases With HapMap

Determining the patterns of DNA sequence variation in the human genome is a useful first step toward identifying the genetic basis of a common disease. A haplotype map (HapMap), aimed at describing these variation patterns across the entire genome, has been recently developed by the International HapMap Consortium. In this article, we present a novel statistical model for directly characterizing specific sequence variants that are responsible for disease risk based on the haplotype structure provided by HapMap. Our model is developed in the maximum-likelihood context, implemented with the EM algorithm. We perform simulation studies to investigate the statistical properties of this disease-sequencing model. A worked example from a human obesity study with 155 patients was used to validate this model. In this example, we found that patients carrying a haplotype constituted by allele Gly16 at codon 16 and allele Gln27 at codon 27 genotyped within the β2AR candidate gene display significantly lower body mass index than patients carrying the other haplotypes. The implications and extensions of our model are discussed.

[1]  T. Louis Finding the Observed Information Matrix When Using the EM Algorithm , 1982 .

[2]  E. Lander,et al.  Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. , 1989, Genetics.

[3]  R. Doerge,et al.  Empirical threshold values for quantitative trait mapping. , 1994, Genetics.

[4]  I. Hall,et al.  Implications of Genetic Variability of Human β2-adrenergic Receptor Structure , 1995 .

[5]  M. Lynch,et al.  Genetics and Analysis of Quantitative Traits , 1996 .

[6]  P. Eriksson,et al.  Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. , 1997, The Journal of clinical investigation.

[7]  D. A. Mason,et al.  A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.

[8]  T. Lewander,et al.  Pharmacogenomics to predict drug response. , 2000, Pharmacogenomics.

[9]  R Judson,et al.  The predictive power of haplotypes in clinical response. , 2000, Pharmacogenomics.

[10]  David R. Anderson,et al.  Model selection and inference : a practical information-theoretic approach , 2000 .

[11]  T. C. Nesbitt,et al.  fw2.2: a quantitative trait locus key to the evolution of tomato fruit size. , 2000, Science.

[12]  S. P. Fodor,et al.  Blocks of Limited Haplotype Diversity Revealed by High-Resolution Scanning of Human Chromosome 21 , 2001, Science.

[13]  J. Bader The relative power of SNPs and haplotype as genetic markers for association tests. , 2001, Pharmacogenomics.

[14]  T. Mackay The genetic architecture of quantitative traits. , 2001, Annual review of genetics.

[15]  Peter H. Westfall,et al.  Testing Association of Statistically Inferred Haplotypes with Discrete and Continuous Traits in Samples of Unrelated Individuals , 2002, Human Heredity.

[16]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[17]  G. Casella,et al.  Joint linkage and linkage disequilibrium mapping of quantitative trait loci in natural populations. , 2002, Genetics.

[18]  Lon R. Cardon,et al.  A first-generation linkage disequilibrium map of human chromosome 22 , 2002, Nature.

[19]  R. Weinshilboum Inheritance and drug response. , 2003, The New England journal of medicine.

[20]  Rongling Wu,et al.  A haplotype-based algorithm for multilocus linkage disequilibrium mapping of quantitative trait loci with epistasis. , 2003, Genetics.

[21]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.

[22]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[23]  E. Snyder,et al.  The human obesity gene map: the 2002 update. , 2003, Obesity research.